Medical DevicesSilver report

Published April 2026Insight Research21 min read2026 Edition21 sources, 21 primary-gradeVery high source depth

Thailand Medical Devices Market Intelligence

Thailand's medical-devices market ~THB 150B, ~85% imports. Sri Trang Gloves (STGT) anchors domestic consumables; MNC subsidiaries (Siemens Healthineers, GE HealthCare, Philips, Medtronic, Abbott, J&J MedTech, Olympus) lead equipment. Medical tourism, ageing, EEC Medical Hub drive demand.

Key takeaways

1
Thailand's medical-device market reached approximately in FY2024, compounding ~ annually from FY2020 post-COVID. Imports dominate at ~ of value; domestic manufacturing concentrates in consumables.
2
Sri Trang Gloves (SET: STGT, FY2024 revenue ~) is the anchor domestic manufacturer — world top-5 medical, examination glove producer by capacity, vertically integrated under parent Sri Trang Agro-Industry (rubber-to-gloves supply chain). Beyond STGT, domestic manufacturing is fragmented across syringes, PPE, surgical masks, and specialty consumables.
3
MNC Thai subsidiaries lead equipment imports: Siemens Healthineers, GE HealthCare, Philips in imaging, monitoring; Medtronic, J&J MedTech in surgical, cardiac, orthopedic; Abbott in diagnostics, continuous-glucose monitoring; Olympus in endoscopy. Each dominates its specialty segment; collectively ~ of market value.
4
Medical tourism, ageing demographics, private-hospital capex drive structural demand. Thailand's ~ annual medical tourists, 400+ JCI-accredited hospitals support continuous imaging, surgical, specialty-device procurement. EEC Medical Hub framework, BOI 13-year tax holiday aim to attract FDI medical-device manufacturing but execution has been slow.
5
Our read: Thai medical devices is a structural-growth platform with bifurcated supply. Consumables are domestically-manufactured, export-oriented (STGT, glove, PPE cluster). Equipment is import-dependent. BOI, EEC Medical Hub policy pipeline is the wildcard for shifting this mix toward domestic manufacturing; without material FDI wins Thailand remains equipment-import-dependent through decade.

Thai FDA, TCELS, EEC, BOISTGT FY2024 56-1MNC subsidiary disclosuresFTI medical clusterUN Comtrade, SCB EIC

Data as of: April 2026 edition · FY2024 full-year anchor · 2026-Q1 tracking pending · FY2025 primary-source ingest queued

Executive summary

What this report covers, and the thesis in one paragraph

Thailand's medical-device market reached approximately in FY2024 per Thai FDA, FTI, industry-body aggregates, compounding ~ annually since FY2020 as the post-COVID medical-services recovery, specialty-equipment capex cycle played out. Imports dominate the value stack at approximately of total, reflecting Thailand's limited domestic capability in complex imaging, monitoring, implantable, diagnostic equipment. Domestic manufacturing is concentrated in medical consumables — gloves (Thailand is a world top-3 producer by capacity), syringes, PPE, surgical masks, sutures, catheters, and specialty single-use items. Export of these consumables is material; Thailand is a net exporter in HS 4014/4015 (rubber gloves) but a net importer in HS 9018 (medical instruments) and HS 9022 (X-ray, imaging).^{[, , ]}

Sri Trang Gloves (SET: STGT) is the anchor domestic manufacturer — FY2024 revenue approximately , world top-5 medical, examination glove producer by capacity, vertically integrated via parent Sri Trang Agro-Industry (STA) which supplies natural, synthetic rubber feedstock. MNC Thai subsidiaries lead equipment supply: Siemens Healthineers (CT, MRI, ultrasound, lab IVD), GE HealthCare (imaging, patient monitoring, 2023 spinoff from GE), Philips (imaging, patient monitoring, respiratory, sleep), Medtronic (surgical, cardiac, diabetes, neurology — dominant in Thai catheter, pacemaker, diabetes-pump supply), Abbott (diagnostics, FreeStyle Libre, nutrition), J&J MedTech (surgical, orthopedic via DePuy Synthes, vision via Acuvue), Olympus (endoscopy, surgical imaging). Beyond these top-7, ~1,500+ licensed importers, distributors serve specialty, long-tail segments.^{[, , , , , , , ]}

Our thesis: Thai medical devices is a bifurcated-supply platform with structural growth. Consumables domestic, export-oriented; equipment import-dependent. Structural demand drivers — medical tourism, ageing demographics, private-hospital capex — are durable; the strategic question is whether BOI, EEC Medical Hub policy can shift the equipment-supply mix toward domestic manufacturing (either MNC Thai plants or local OEMs). Near-term variables: glove-cycle recovery for STGT (post-COVID oversupply cycle), MoPH, NHSO equipment procurement budgets, medical-tourism arrivals, specialty capex. Medium-term: BOI FDI wins, TCELS, Mahidol ecosystem spinouts, EEC Medical Hub positioning vs Singapore, Malaysia.^{[, , , ]}

Thai FDA, STGT 56-1, MNC subsidiary disclosures, UN Comtrade, BOI, EEC, TCELSSCB EIC outlook

Data as of: April 2026 edition · FY2024 full-year anchor

Market size at a glance

Thailand medical-device market, 2020–2024 (THB B, FY2024 anchor)

2020

Market value

~ $2.75B

YoY

base

Driver

COVID PPE, glove demand spike offsets equipment capex slowdown; STGT record year.

2021

Market value

~ $3.19B

YoY

+16%

Driver

COVID continued; ventilator, testing, diagnostic demand; equipment capex recovery partial.

2022

Market value

~ $3.62B

YoY

+14%

Driver

Medical-services normalisation; elective-surgery return drives surgical, imaging capex.

2023

Market value

~ $4.06B

YoY

+12%

Driver

Medical tourism rebound accelerates; hospital-sector capex cycle active; glove oversupply compresses STGT.

2024

Market value

~ $4.35B

YoY

+7%

Driver

Steady-state growth; imaging, surgical equipment, consumables diversified.

Year	Market value	YoY	Driver
2020	~ $2.75B	base	COVID PPE, glove demand spike offsets equipment capex slowdown; STGT record year.
2021	~ $3.19B	+16%	COVID continued; ventilator, testing, diagnostic demand; equipment capex recovery partial.
2022	~ $3.62B	+14%	Medical-services normalisation; elective-surgery return drives surgical, imaging capex.
2023	~ $4.06B	+12%	Medical tourism rebound accelerates; hospital-sector capex cycle active; glove oversupply compresses STGT.
2024	~ $4.35B	+7%	Steady-state growth; imaging, surgical equipment, consumables diversified.

Thai FDA, FTI, UN Comtrade aggregates

Data as of: April 2026 · FY2024 full-year anchor

Market size combines FDA-registered device sales, UN Comtrade import value, domestic manufacturer production. 2020-2021 spike is COVID-specific (PPE, ventilator, testing); 2022-2024 reflects more structural demand.

Segment mix

Thai medical device market by segment (FY2024 share, directional)

Imaging, monitoring

~25%

Driver

Siemens Healthineers, GE HealthCare, Philips. CT, MRI, ultrasound, patient monitors. Hospital capex cycle.

Consumables (gloves, syringes, PPE)

~22%

Driver

Domestic-dominated. STGT, ~500 smaller manufacturers. Export-oriented.

Surgical, orthopedic, implantable

~20%

Driver

Medtronic, J&J MedTech. Pacemaker, catheter, orthopedic, surgical instrument. Specialty-hospital demand.

Dental, rehab, other

~18%

Driver

Diverse operators, distributors. Dental chair, implant, rehabilitation equipment.

IVD, diagnostics

~15%

Driver

Abbott, Siemens Healthineers, Roche Diagnostics. Clinical chemistry, molecular, point-of-care.

Segment	Share	Driver
Imaging, monitoring	~25%	Siemens Healthineers, GE HealthCare, Philips. CT, MRI, ultrasound, patient monitors. Hospital capex cycle.
Consumables (gloves, syringes, PPE)	~22%	Domestic-dominated. STGT, ~500 smaller manufacturers. Export-oriented.
Surgical, orthopedic, implantable	~20%	Medtronic, J&J MedTech. Pacemaker, catheter, orthopedic, surgical instrument. Specialty-hospital demand.
Dental, rehab, other	~18%	Diverse operators, distributors. Dental chair, implant, rehabilitation equipment.
IVD, diagnostics	~15%	Abbott, Siemens Healthineers, Roche Diagnostics. Clinical chemistry, molecular, point-of-care.

Thai FDA, FTI, industry-body aggregates, MNC subsidiary disclosures

Data as of: April 2026 · FY2024 segment reconciliation

Shares directional. Consumables share would be larger if export volumes included; shown here is domestic consumption share.

Analyst framing

Why this profile is worth unlocking

Thai medical devices is bifurcated supply, structural growth. STGT anchors domestic consumables; MNC subs lead equipment imports. BOI, EEC Medical Hub policy pipeline is the wildcard for FDI, domestic manufacturing shift. Near-term: glove-cycle, hospital capex; medium-term: FDI wins.

Operator playbooks

STGT domestic anchor, seven MNC subsidiaries leading equipment

Sri Trang Gloves (SET: STGT) is the domestic-manufacturing anchor — world top-5 medical, examination glove producer by capacity, FY2024 revenue ~THB 27B. Parent Sri Trang Agro-Industry (STA) is the natural-rubber, synthetic-rubber feedstock supplier, giving STGT vertical integration unmatched by Malaysian glove peers (Top Glove, Hartalega, Kossan). Post-COVID glove oversupply cycle compressed margins 2022-2024; recovery pace is the binding near-term variable. Export-oriented (~80% of revenue) with US, EU, Japan, ASEAN key markets.

Siemens Healthineers Thailand leads MNC imaging, IVD (CT, MRI, ultrasound, molecular, clinical chemistry). GE HealthCare Thailand competes directly on imaging, patient monitoring after its 2023 spinoff from GE. Philips Thailand covers imaging, monitoring, sleep, respiratory (post-2021 CPAP recall still affecting brand). Collectively these three MNCs hold ~25% of Thai medical-device market value via imaging, monitoring dominance.

Medtronic Thailand leads surgical, cardiac, diabetes, neurology devices — dominant in Thai pacemaker, catheter, diabetes-pump, neuromodulation supply. J&J MedTech Thailand covers surgical (Ethicon), orthopedic (DePuy Synthes), vision, ENT, cardiovascular. Abbott Thailand leads diagnostics, FreeStyle Libre continuous-glucose-monitor, cardiovascular. Olympus Thailand is effectively the monopoly endoscopy supplier for Thai GI, respiratory, bronchoscopy. The long tail of ~1,500+ licensed importers, distributors, small domestic manufacturers serves specialty, dental, rehab, consumables segments.

Competitive concentration

Inferred share of Thai medical-device market value (FY2024, directional)

Sri Trang Gloves (SET: STGT)

~12%

Tier

Listed domestic

Role

Medical, exam glove world top-5.

Siemens Healthineers Thailand

~10%

Tier

MNC imaging

Role

CT, MRI, ultrasound, IVD.

Medtronic Thailand

~9%

Tier

MNC surgical/cardiac

Role

Pacemaker, catheter, diabetes, neuro.

GE HealthCare Thailand

~8%

Tier

MNC imaging

Role

Imaging, monitoring.

Philips Thailand

~8%

Tier

MNC imaging

Role

Imaging, monitoring, respiratory.

Abbott Thailand

~6%

Tier

MNC diagnostics

Role

Diagnostics, CGM, cardiovascular.

J&J MedTech Thailand

~5%

Tier

MNC surgical/ortho

Role

Surgical, orthopedic, vision.

Olympus Thailand

~4%

Tier

MNC endoscopy

Role

GI, respiratory endoscopy near-monopoly.

Long tail (distributors, specialty, small domestic)

~38%

Tier

Mixed

Role

~1,500+ importers, consumables, specialty.

Operator	Share	Tier	Role
Sri Trang Gloves (SET: STGT)	~12%	Listed domestic	Medical, exam glove world top-5.
Siemens Healthineers Thailand	~10%	MNC imaging	CT, MRI, ultrasound, IVD.
Medtronic Thailand	~9%	MNC surgical/cardiac	Pacemaker, catheter, diabetes, neuro.
GE HealthCare Thailand	~8%	MNC imaging	Imaging, monitoring.
Philips Thailand	~8%	MNC imaging	Imaging, monitoring, respiratory.
Abbott Thailand	~6%	MNC diagnostics	Diagnostics, CGM, cardiovascular.
J&J MedTech Thailand	~5%	MNC surgical/ortho	Surgical, orthopedic, vision.
Olympus Thailand	~4%	MNC endoscopy	GI, respiratory endoscopy near-monopoly.
Long tail (distributors, specialty, small domestic)	~38%	Mixed	~1,500+ importers, consumables, specialty.

Thai FDA, FTI, MNC subsidiary disclosures

Data as of: April 2026 · FY2024 operator reconciliation

Shares directional. Top-7 MNCs, STGT ~62% of market value combined; remainder is specialty, long-tail importers, small domestic consumables.

Unlock the full report

Six-operator playbook, STGT, Sri Trang Agro-Industry group structure, Medical Device Act, EEC Medical Hub regulatory arc, concentration, positioning matrix, 2031 scenarios, and the full companies module are behind the unlock.

Unlock full report·$149-$199

Need more than the web report? Ask for a scoped export or source appendix.

Every report keeps visible citations and source metadata. Terms.

Key figures

Selected anchors from the report evidence pack.

FY2023

~USD 1.5–2.5B/yr

Thailand Medical Device Import Value

Thai FDA, Thai Customs Department, MOPH Annual Report

FY2023

~60–70% of private-hospital procurement

DKSH and Zuellig Pharma Combined Distribution Reach

DKSH Holding Annual Report, industry channel surveys, Thai FDA import statistics

FY2023

~USD 3–4B/yr

Thailand Medical Device Export Value

Thai Customs Department, THAIMED, BOI Thailand, Sri Trang Gloves Annual Report

FY2024

~60–70 facilities

JCI-Accredited Hospitals in Thailand

Joint Commission International, BDMS Annual Report, MOPH

FY2023

~40–50B pieces/yr

Sri Trang Gloves Annual Production Capacity

Sri Trang Gloves Annual Report, THAIMED

Related reports

Thailand Diagnostic Lab & Imaging Deep Dive

Deep-dive into Thai diagnostic lab, medical imaging ~THB 55-70B FY2024. Hospital-integrated clinical labs at Bumrungrad, Samitivej, Bangkok Hospital, Piyavate, Ramkhamhaeng, public university hospitals; specialist reference labs (N Health, Thyrocare, LabPlus, Professional Laboratory); medical imaging (X-ray, CT, MRI, PET-CT, ultrasound, nuclear); point-of-care, home-test kits, digital diagnostic. Equipment imported from Siemens Healthineers, GE HealthCare, Philips, Roche, Abbott, Sysmex, Hitachi. 2020-2022 COVID testing surge boosted revenue; post-COVID corporate wellness, health screening, medical tourism return drive recovery. Regulation: Thai FDA MDCD, MoPH NCD screening.

Open report →

Thailand CGM & Wearable Health Tracker 2027 Market Intelligence

Thailand has 5.2 million diagnosed diabetics and 8.7 million pre-diabetes (HbA1c 5.7 to 6.4 percent), with continuous glucose monitor (CGM) adoption (Abbott FreeStyle Libre 3, Dexcom G7, Medtronic Guardian Sensor 4, Roche Accu-Chek SmartGuide) and downstream consumer wearable health-tracker uptake (Oura Ring Gen4, Whoop, Apple Watch, Samsung Galaxy Watch, Huawei Watch D, Garmin Venu) compounding across 2026 to 2027. The 2026 to 2027 catalyst stack includes the NHSO Universal Coverage benefit-schedule bundling of CGM for Type-1 diabetics and gestational diabetes pregnancies (~80,000 to 130,000 reimbursed units) effective Q3 2026; the Thai FDA Q1 2026 over-the-counter reclassification of CGM sensors from Class III prescription-only to Class II pharmacist-counseling status, dropping sensor average selling price from THB 4,800 to 6,500 to THB 1,950 to 2,800; the Krungthai Axa, Bangkok Insurance and Dhipaya wellness-bundle premium tiers covering CGM, Oura Ring and Apple Watch; the Thai metabolic-health interpretation software layer (BeYou by Khon Kaen University, Glucose Goddess Thailand, Vata); the BOI Section 8 medical-device incentive plus corporate income tax deduction for employer-provided wearable wellness benefits; and the Apple, Samsung, Huawei consumer non-invasive glucose research pipeline approaching clinical accuracy by 2027 to 2028. Our read: the 2027 Thai CGM and consumer wearable health-tracker market reaches THB 9 to 15 billion (vs THB 1.4 to 2.3 billion in 2024), with Abbott, Dexcom, Medtronic, Apple, Samsung, Oura, Whoop and Garmin capturing roughly 80 percent share and Thai interpretation-layer brands (BeYou, Glucose Goddess Thailand) plus a parallel-import long tail capturing the remainder.

Open report →

Thailand Capital Markets & Securities Market Intelligence

The Stock Exchange of Thailand hosts ~THB 18T in market cap across ~800 listed companies; Thailand's capital-markets stack extends across TFEX derivatives, ThaiBMA bond market (~THB 16T), 60+ listed REITs, infrastructure funds, and the Government Pension Fund, Social Security Office as the largest institutional participants. Bank-subsidiary brokers dominate dealer activity; a standalone listed tier (ASP, FSS, Trinity, CGS, KGI, MFC) fills niches. SEC Thailand regulates; BOT policy-rate transmission defines cross-asset pricing.

Open report →

Thailand Healthcare Services & Medical Tourism Market Intelligence

Thailand runs Asia's deepest medical-tourism franchise — 60+ JCI-accredited hospitals, ~3-4M medical-tourism visits generating USD 1.5-2B in receipts. BDMS (SET: BDMS) anchors at >THB 110B FY2024 across 50+ hospitals; Bumrungrad (SET: BH) runs >60% international-patient revenue mix. Public insurance (UCS ~47M, SSS ~15M) plus private, international cash-pay shape the payor mix. Physician supply at 0.9-1.0 per 1,000 is the binding workforce constraint on growth.

Open report →